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OBJECTIVES This study determined the incidence of pseudothrombocytopenia during abciximab therapy
administered for percutaneous coronary interventions and compared the clinical course of
patients with pseudothrombocytopenia with the clinical courses of patients with thrombo-
cytopenia and patients with normal platelet counts.
BACKGROUND Although pseudothrombocytopenia has been previously reported during therapy with
abciximab, the incidence and significance of this occurrence are unknown. The failure to
differentiate pseudothrombocytopenia from thrombocytopenia could lead to unnecessary
interruption of abciximab infusions or to platelet transfusions.
METHODS The incidences of pseudothrombocytopenia and thrombocytopenia were determined in four
large placebo-controlled abciximab trials: c7E3 Fab Antiplatelet Therapy in Unstable
Refractory Angina (CAPTURE), Evaluation of 7E3 for the Prevention of Ischemic
Complications (EPIC), Evaluation of Percutaneous Transluminal Coronary Angioplasty to
Improve Long-term Outcome of c7E3 GpIIb/IIIa Receptor Blockade (EPILOG) and
Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT). The clinical features,
bleeding complications and major clinical outcomes of patients with pseudothrombocytopenia
and those with thrombocytopenia were compared with each other and with those of patients
with normal platelet count.
RESULTS Pseudothrombocytopenia occurred in 2.1% (95% confidence intervals [CI]: 1.7%, 2.5%) of
abciximab-treated patients and in 0.6% of placebo-treated patients (p , 0.001). Thrombo-
cytopenia occurred in 3.7% (95% CI: 3.2%, 4.2%) of abciximab-treated patients and in 1.8%
(95% CI: 1.3%, 2.3%) of placebo-treated patients (p , 0.001). Patients with thrombocyto-
penia had significantly higher rates of major bleeding, major decreases in hemoglobin and
increased transfusion requirements of both blood and platelets compared with those without
thrombocytopenia. By contrast, pseudothrombocytopenic patients did not differ from patients
with normal platelet counts in any of the measures of blood loss or transfusion requirements.
Thrombocytopenic patients, but not those with pseudothrombocytopenia, had increased rates
of revascularization at 30 days and six months. As previously reported, there was also a higher
rate of death and myocardial infarction in the thrombocytopenic patients.
CONCLUSIONS Pseudothrombocytopenia is the cause of more than one third (36.3%) of low platelet counts
in patients undergoing coronary interventions who are treated with abciximab. This study
demonstrates that pseudothrombocytopenia is a benign laboratory condition that does not
increase bleeding, stroke, transfusion requirements or the need for repeat revasculariza-
tion. It is important to recognize pseudothrombocytopenia so that the beneficial effects
of abciximab are not lost by premature termination of therapy. (J Am Coll Cardiol 2000;
36:75– 83) © 2000 by the American College of Cardiology
The role of inhibitors of the platelet fibrinogen receptor (Gp
IIb/IIIa) in the management of acute coronary ischemic
syndromes and percutaneous coronary interventions has
been well established by several large randomized clinical
trials (1–6). Abciximab, a human/mouse chimeric Fab
fragment that binds to the beta3 subunit of the fibrinogen
receptor (7) was the first agent to be approved for percuta-
neous interventions. In the Evaluation of 7E3 for the
Prevention of Ischemic Complications (EPIC) trial, abcix-
imab bolus and infusion resulted in a 35% reduction in the
primary composite end point of death, nonfatal myocardial
infarction (MI) or unplanned revascularization (1). Despite
this benefit, the rate of major hemorrhage was doubled in
the bolus plus infusion treatment arm compared with the
placebo-treated group in EPIC. The Evaluation of Percu-
taneous Transluminal Coronary Angioplasty to Improve
Long-term Outcome of c7E3 GpIIb/IIIa Receptor Block-
ade (EPILOG) and Evaluation of Platelet IIb/IIIa Inhibitor
for Stenting (EPISTENT) stent trials subsequently dem-
onstrated that the rate of major hemorrhage can be lowered
to that of patients not receiving abciximab by using lower
weight-adjusted doses of concomitant heparin therapy and
by early removal of arterial sheaths (3,4).
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Despite the overall low rate of bleeding, the development
of thrombocytopenia during abciximab therapy is associated
with an increased rate of hemorrhage (8). Although the
nadir platelet count during abciximab-induced thrombocy-
topenia is typically about 75K (8), this complication occa-
sionally results in acute profound thrombocytopenia
(,20K), requiring cessation of abciximab infusion and
platelet transfusions (9). Abciximab-induced pseudothrom-
bocytopenia (PTCP) has also been previously reported in
early clinical studies (10), but its incidence in the large-scale
clinical trials that have defined the current role of abciximab
in acute coronary ischemic syndromes is unknown. Al-
though PTCP is generally considered to be an in vitro
artifact that does not require therapy, its significance in the
setting of abciximab therapy for percutaneous coronary
interventions (PCIs) has not been previously studied. Ac-
cordingly, in this paper, we report on the frequency of
occurrence of PTCP in four major abciximab trials and
compare the clinical course of patients with PTCP to those
with thrombocytopenia.
METHODS
Study populations. The occurrence of PTCP was evalu-
ated in four randomized trials of abciximab, which have
been previously described in detail (1–4). These trials were
approved by the institutional review board of the participat-
ing institutions. The EPIC trial was a prospective, random-
ized double-blind trial of 2,099 high risk intervention
patients who received either a bolus plus infusion of placebo,
a bolus of abciximab and an infusion of placebo or a bolus
and 12 h infusion of abciximab (1). For the purposes of this
study, the abciximab bolus only arm and the bolus plus
infusion groups were combined. The c7E3 Fab Antiplatelet
Therapy in Unstable Refractory Angina (CAPTURE) trial
randomized 1,265 patients with refractory unstable angina
to an 18 to 24 h infusion of abciximab or placebo before
planned percutaneous intervention. The abciximab or pla-
cebo infusion was continued for 1 h after the PCI (2). The
EPILOG trial was a prospective, double-blinded study in
which 2,792 patients undergoing urgent or elective PCI
were randomized to receive abciximab with standard-dose
weight-adjusted heparin, abciximab with low-dose weight-
adjusted heparin or placebo with standard-dose weight-
adjusted heparin (3). The EPISTENT trial was a study of
2,399 patients undergoing elective PCI who were randomly
assigned to receive stenting plus placebo, stenting plus
abciximab or balloon angioplasty plus abciximab (4).
Platelet counts. Blood samples for platelet counts were
obtained at 30 min, 2, 12 and 24 h after study agent
administration. Follow-up platelet counts were obtained at
four days and at one, two and four weeks. If a platelet count
of ,100,000/Ul was obtained that also represented a
decrease of at least 25% below baseline value, then addi-
tional platelet counts in EDTA, citrate and heparin antico-
agulants were drawn. A smear from blood in each of these
anticoagulants was requested. The presence of platelet
aggregates on any sample obtained for platelet count was
reported.
Definitions of thrombocytopenia and PTCP. The dis-
tinction between thrombocytopenia and PTCP was made
for all trials by the same reviewer (D.C.S.), who was blinded
to the treatment groups. Thrombocytopenia was defined by
a platelet count ,100 3 109/liter and with a $25% decrease
from the baseline count without evidence for PTCP.
Pseudothrombocytopenia required one or more of the fol-
lowing: 1) a difference between the platelet count in two
anticoagulants, with one having a count at least 20% lower
than the count in the comparison anticoagulant. In this
study, the anticoagulants that were compared were ethylene
diamine tetra acetic acid (EDTA) and citrate in more than
90% of cases, 2) platelet clumping on a blood smear made
from anticoagulated blood, 3) a normal platelet count on a
blood smear made from nonanticoagulated blood or 4) an
unexplained drop in platelet count at 30 min to 4 h after
abciximab bolus with recovery to a normal count within 4 h
after the nadir. This last criterion was developed when
review of the first cases revealed that there was a frequent
association between low platelet counts and one of the other
three criteria for PTCP at this time point.
Statistical analyses. Logistic regression was performed on
discrete outcomes of interest using indicator variables for: 1)
PTCP, 2) thrombocytopenia, 3) neither and 4) treatment as
independent variables. Interaction terms between treatment
and thrombocytopenia, PTCP and neither were also tested
to see if associations differed between treatment groups; if
an interaction test was positive, the association of interest
was examined separately in the abciximab and placebo
groups. A linear model was used to test for associations
between individual characteristic outcomes and treatment.
Each characteristic was studied as a dependent variable.
Independent variables were indicators for the status of
thrombocytopenia, treatment and interactions. A chi-square
test was used to compare the four study differences.
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
CAPTURE 5 c7E3 Fab Antiplatelet Therapy in
Unstable Refractory Angina trial
EDTA 5 ethylene diamine tetra acetic acid
EPIC 5 Evaluation of 7E3 for the Prevention of
Ischemic Complications trial
EPILOG 5 Evaluation of Percutaneous
Transluminal Coronary Angioplasty to
Improve Long-term Outcome of c7E3
Gp IIb/IIIa Receptor Blockade trial
EPISTENT 5 Evaluation of Platelet IIb/IIIa Inhibitor
for Stenting trial
LIBS 5 ligand induced binding sites
MI 5 myocardial infarction
PCI 5 percutaneous coronary intervention
PTCP 5 pseudothrombocytopenia
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Study limitations. Our study has some limitations.
Thrombocytopenia or PTCP may have occurred before or
after outcome events. Thus, these analyses examined the
association of PTCP and thrombocytopenia with other
outcomes rather than any cause-effect relationship. The
etiology of thrombocytopenia was not investigated rigor-
ously in most cases. A potential interaction between heparin
and the occurrence of thrombocytopenia and PTCP could
not be defined.
RESULTS
Thrombocytopenia occurred in 205 of 5,476 abciximab-
treated patients (3.7%) and in 56 of 3,079 placebo-treated
patients (1.8%; p , 0.001, Fisher’s exact test). Pseudo-
thrombocytopenia occurred in 2.1% (117/5,476) of
abciximab-treated patients and in 0.6% (17/3,079) of
placebo-treated patients (p , 0.001, Fisher’s exact test).
The rates of PTCP in placebo-treated patients in the
individual trials were 0.6% (CAPTURE), 1.3% (EPIC),
0.2% (EPILOG) and 0.2% (EPISTENT). The rates of
PTCP in abciximab-treated patients in the individual trials
were 4.0% (CAPTURE), 1.7% (EPIC), 1.9% (EPILOG)
and 2.1% (EPISTENT). The frequency of premature ter-
mination of planned infusion was 6.5% (195/3,006) for the
patients with normal platelet counts treated with placebo
and 7.5% (384/5,154) for this group when treated with
abciximab. Thrombocytopenic patients had a much higher
rate of early cessation of the infusion with 44.6% (25/56) of
the placebo-treated and 34.6% (71/205) of the abciximab-
treated patients being affected. None (0/17) of the PTCP
patients treated with placebo and 12.0% (14/117) of the
PTCP patients treated with abciximab had early termina-
tion of therapy.
Table 1 shows the clinical characteristics of all patients
from the four trials. As previously reported during abcix-
imab therapy (8), patients with thrombocytopenia were
older than those with normal platelet counts (p 5 0.0018).
There was a trend (p 5 0.09) toward an association between
older age and the occurrence of PTCP. Patients with PTCP
in the placebo-treated group were more likely to have
peripheral vascular disease and tended to be women. When
all of the groups were combined, there were no significant
differences in any of the demographic or clinical character-
istics between the abciximab-treated and the placebo-
treated patients (Table 1, last column on the right), sug-
gesting that randomization successfully balanced these
characteristics.
Tables 2–4 show the in-hospital bleeding and transfusion
requirements in the three groups of patients. Table 2
includes all patients, Table 3 is for the group with coronary
artery bypass grafting (CABG), and Table 4 is for patients
who did not have CABG. Patients with thrombocytopenia
had significantly higher rates of maximum bleeding, major
decreases in hemoglobin, and increased transfusion require-
ments for both blood and platelets. Overall, 67.9% of Ta
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patients with thrombocytopenia in the placebo-treated
group and 26.3% of patients with abciximab-induced
thrombocytopenia received blood transfusions. By contrast,
the proportions of patients receiving blood and platelet
transfusions in the PTCP group were similar to those in the
group of patients without lowered platelet counts. The
decrease in platelet count was the only significant hemato-
logical difference between the PTCP and the “neither”
groups. When all three groups were combined, the patients
treated with abciximab were more likely to have a major
decrease in hemoglobin and had a larger maximum decrease
in the platelet count. There was a trend (p 5 0.075) toward
increased transfusion of 1 to 2 U of blood in abciximab-
treated patients compared with those who received pla-
cebo. However, there were also important differences in
bleeding depending on the heparin strategy, with no
elevated bleeding noted with reduced heparin regimens
(3,4).
The 30-day clinical outcomes of death, MI and stroke are
shown in Table 5. There was a higher rate of death in the
thrombocytopenic group (p , 0.001) compared with the
“neither” group. There was a trend toward increased death
in the placebo-treated PTCP group (p 5 0.051). There was
a higher rate of MI in the placebo-treated thrombocytope-
nic group compared with the “neither” group. When throm-
bocytopenic, PTCP and “neither” groups were combined,
the patients treated with abciximab had lower rates of MI
(p 5 0.0069) compared with those treated with placebo.
The frequency of stroke was very low in all groups and was
not increased by thrombocytopenia or PTCP. Patients with
thrombocytopenia, especially those who received placebo,
had significantly increased rates of revascularization with
PCI and CABG at 30 days.
At six months (Table 6), the higher rate of death in the
thrombocytopenia group versus the “neither” group per-
sisted (p , 0.001). There was also a higher rate of MI and
repeat revascularization with CABG (but not PCI) in the
thrombocytopenia group compared with the neither
group. When all three groups were combined, the pa-
tients treated with abciximab had lower rates of MI and
need for repeat revascularization compared with those
treated with placebo.
At 30 days and at six months, there was no increase in
death, MI, stroke or need for repeat revascularization in the
PTCP group compared with the “neither” group.
DISCUSSION
In the four studies that were reviewed for this report, PTCP
occurred in 2.1% (117/5,476) of abciximab-treated patients
and in 0.6% (17/3,079) of placebo-treated patients (p ,
0.001). Pseudothrombocytopenia was judged to be the
etiology of 32.2% of all cases of low platelet counts in the
overall study populations (placebo- and abciximab-treated)
and 36.3% of all cases in the abciximab-treated group. Thus,
it is important to recognize PTCP, a condition that doesTa
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not require specific therapy or the premature cessation of
abciximab from thrombocytopenia, a condition that may
mandate an intervention.
Christopoulos and Machin (10) first reported the occur-
rence of PTCP in 19% of 21 patients participating in early
clinical studies of Gp IIb/IIIa inhibition in which chimeric
whole molecule 7E3 IgG or the c7E3 Fab fragment was
infused for up to 96 h (10). The higher percentage of PTCP
in their study compared with the current report probably
reflects the small sample size. Other factors that could
account for this difference include the molecular form of
abciximab that was used or the long duration of therapy.
The higher PTCP rate in the CAPTURE trial (4%) in
which an 18 to 26 h infusion was used compared with the
other studies (1.7 to 2.1%) in which a 12 h infusion or bolus
only was used emphasizes the importance of the treatment
regimen. The patients reported in these four studies were
treated for the first time with abciximab. Although a
preliminary study (11) suggests that the incidence of throm-
bocytopenia is slightly increased (to 4.6%) with repeat
dosing, further analyses of the effects of readministration on
both thrombocytopenia and PTCP are warranted and are
ongoing.
Prior studies of PTCP. Previous reports have documented
the occurrence of PTCP in up to 0.2% of the healthy
population and in 1.9% of hospitalized patients (12–14).
Although PTCP is an infrequent condition, it accounts for
a sizable fraction (7.5 to 15.3%) of all cases of “thrombocy-
topenia” that are referred to hematologists for further
evaluation (15). The phenomenon of PTCP that occurs in
the absence of abciximab therapy is due to platelet autoan-
tibodies that recognize usually cryptic platelet antigens that
are exposed in vitro. The presence of certain anticoagulants
(especially EDTA), low temperatures and prolonged time
intervals between blood draws and assays are factors that
enhance the occurrence of PTCP (16–19). The autoanti-
bodies are usually IgG or IgM with the most commonly
reported antigenic target being platelet glycoprotein IIb (16)
although other antigens including phospholipids have been
described (18). Ethylene diamine tetra acetic acid is the
most commonly reported anticoagulant to induce PTCP.
The calcium chelating activity of EDTA is thought to
remove calcium from binding sites within Gp IIb or Gp
IIIa, resulting in exposure or conformational alteration of
the molecule(s), thereby allowing the previously cryptic
antigen to interact with the autoantibody (17). As a result of
the frequent association with EDTA anticoagulant a com-
monly recommended method to screen for this phenome-
non and the method most commonly used in the studies in
this report is to obtain simultaneous platelet counts in
EDTA and sodium citrate anticoagulants. However, the
term “EDTA-dependent PTCP” has been rejected by some
investigators, since PTCP has been observed in citrate
anticoagulants and even in nonchelating anticoagulants
such as hirudin and D-phenylalanine-proline-arginine-
chloromethyl ketone (19). Bizzaro et al. (17) noted that in
15 of their 93 cases (10.8%) with PTCP and antiplatelet
antibodies, agglutination occurred in citrate at room tem-
perature (17). In this study, 14 of the 117 cases of PTCP
that occurred during abciximab therapy were documented to
occur in the presence of citrate anticoagulant.
Since the autoantibodies that induce PTCP often are
most active in a time-dependent fashion at 4 to 20° C, it has
been suggested that the most reliable way to obtain accurate
platelet counts is to perform platelet counts on blood at
37° C (17). However, even this method will cause a few
cases to be mislabeled since approximately 17% of autoan-
tibodies are reactive at 37°C in the presence of anticoagu-
lants (17). The autoantibodies that are reactive at 37°C and
in citrate are more likely to be of the IgM class (17). The
gold standard for differentiating PTCP from thrombocyto-
penia may, therefore, be to perform a platelet count on
nonanticoagulated blood obtained by finger stick, in which
case a normal platelet count should be obtained. In contrast,
a blood smear prepared from EDTA-anticoagulated blood
typically reveals platelet clumping.
The source of the autoantibodies that are thought to
cause PTCP is unknown. Sakurai et al. (20) reported that a
group of patients who developed PTCP during hospitaliza-
tion had been treated with antibiotics 4 to 10 days before
the onset of this condition. They hypothesized that the
autoantibodies first arose to antibiotics then cross-reacted to
platelet membranes. They demonstrated that presupple-
mentation of EDTA tubes with aminoglycosides prevented
PTCP and that aminoglycosides added after the onset of
platelet clumping could dissociate the aggregates (20).
However, there was no apparent correlation between the
antibiotic that the patient had taken therapeutically and the
antibiotic that was most effective in inhibiting platelet
clumping, casting doubt on the theory that antiplatelet
antibodies arise from cross-reacting antibodies to these
drugs. Another theory for the origin of the autoantibodies
directed to platelets is that they are involved in removing
senescent circulating platelets (17).
Potential mechanisms for abciximab-induced PTCP.
The etiology of the increased prevalence of PTCP in
abciximab-treated patients is also obscure. Christopoulos
and Machin (10) performed flow cytometric analysis of
platelet surface IgG in platelets from two patients with
abciximab-induced PTCP and demonstrated a time- and
room temperature-dependent increase in surface IgG,
which was not present on EDTA samples taken before the
infusion of c7E3 or in citrate anticoagulated samples taken
during the infusion (10). Among 19 patients receiving
c7E3-Fab, the one with the most severe PTCP also had the
most surface IgG (10). This finding led Christopoulos and
Machin to propose that there might be naturally occurring
anti-Fab antibodies and that these might bridge platelets to
81JACC Vol. 36, No. 1, 2000 Sane et al.
July 2000:75–83 Abciximab-induced Pseudothrombocytopenia
form agglutination. Another possibility is that the binding
of the Fab fragment to the beta3 component of the
fibrinogen receptor could alter the conformation of the
molecule and, in concert with the anticoagulant-induced
changes, enhance access of autoantibodies to Gp IIb or
other platelet antigens. Abciximab is known to induce the
expression of conformational changes in the fibrinogen
receptor, as detected by the expression of novel antigens
(ligand induced binding sites [LIBS]) (21,22). The poten-
tial for abciximab-induced conformational changes in the
fibrinogen receptor and the ability of some platelet autoan-
tibodies to react at 37° C also raises the possibility that the
mechanisms for PTCP and thrombocytopenia during ab-
ciximab therapy could be related. Thus, it is possible that
abciximab alone, in the absence of anticoagulants, is ade-
quate to expose the cryptic epitope for warm-reacting
platelet autoantibodies, leading to the immune-mediated
clearance of platelets and thrombocytopenia. This hypoth-
esis is consistent with the observation that the induction of
LIBS epitopes on platelets after abciximab therapy is in-
versely correlated with the platelet count (21). This possi-
bility is also attractive because of the relative high frequency
of PTCP as a cause of low platelet counts with abciximab
therapy and by the fact that the mechanism for abciximab-
induced thrombocytopenia remains unknown.
Clinical implications of abciximab-induced thrombocy-
topenia and PTCP. Despite the possibility that the mech-
anisms for PTCP and thrombocytopenia are related, it is
clear that the clinical courses of the entities are distinct.
Patients with thrombocytopenia had a higher rate of death
and MI than those with PTCP and those with neither
condition. Furthermore, patients with thrombocytopenia,
but not PTCP, had much higher rates of bleeding and
transfusion requirements. The onset of thrombocytopenia,
especially when severe, results in the cessation of abciximab
infusion and may prompt platelet transfusions. These ac-
tions, while appropriate in the case of profound thrombo-
cytopenia (9), should be considered cautiously when the
platelet decrement is less severe, for two reasons. First,
abciximab-treated thrombocytopenic patients had better
outcomes than did those who developed thrombocytopenia
on placebo. Abciximab reduced the rates of death, MI and
revascularization without increased bleeding, despite the
occurrence of thrombocytopenia. Indeed, the thrombocyto-
penic group appeared to accrue the greatest benefit from
abciximab therapy. The second caveat is that the develop-
ment of a low platelet count during abciximab therapy
represented PTCP in slightly more than one-third (36.3%)
of patients.
Cessation of the abciximab infusion or platelet transfu-
sion could lead to an unnecessary abrogation of the benefi-
cial effects of abciximab therapy. The rate of premature
termination of therapy was much higher for thrombocyto-
penic patients (44.6%) than for PTCP patients (12%),
probably because thrombocytopenic patients had a higher
rate of bleeding or because clinicians accurately made the
diagnosis of PTCP in most cases and elected to continue
therapy. It is important that the distinction between PTCP
and thrombocytopenia be made so that the full benefits of
abciximab will be obtained.
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